Key Concepts

India is the world's third-largest pharmaceutical industry by volume and the largest supplier of generic medicines globally, earning the epithet "pharmacy of the world." India supplies ~20% of global generic medicines by volume and provides ~60% of global vaccine demand. However, this export strength masks a structural vulnerability — heavy import dependence on China for Active Pharmaceutical Ingredients (APIs).

India's Pharma Sector: Scale and Significance

  • Market size: India's domestic pharma market is estimated at ~USD 50 billion (2024); total industry (domestic + exports) ~USD 65 billion
  • Exports: India exports to over 200 countries; generics dominate
  • Generics dominance: India is the largest provider of generic drugs to the US (accounts for ~30% of US generic prescriptions by volume)
  • Vaccine supply: Serum Institute of India is the world's largest vaccine manufacturer by volume

The API Problem: China Dependence

Active Pharmaceutical Ingredients (APIs) are the biologically active components in medicines. Bulk drugs (another term) form the raw material for finished formulations.

India imported APIs and bulk drugs worth approximately Rs 377 billion in 2023–24, of which China accounted for approximately 70% of imports (in specific antibiotic categories, the share is as high as 87%). China's share in India's API imports rose from ~70% in 2019 to ~72% in 2022, and remains critically high despite policy interventions.

This dependence creates strategic vulnerability — during COVID-19 supply disruptions, Indian manufacturers faced shortage of key antibiotic and paracetamol APIs sourced from China.

Production Linked Incentive (PLI) Scheme for Pharma

The Government launched two pharma-related PLI schemes:

PLI for Bulk Drugs (APIs)

  • Outlay: Rs 6,940 crore
  • Targets 41 critical APIs (antibiotics, anti-retrovirals, vitamins) where India is >80% import dependent
  • Investment achieved: Rs 4,570 crore by March 2025 (exceeding initial committed targets)
  • Production capacity created for 25 targeted products; cumulative sales Rs 1,817 crore
  • Bulk Drug Parks (3 approved: Himachal Pradesh, Andhra Pradesh, Gujarat) with shared infrastructure

PLI for Finished Dosage Formulations (FDF)

  • Targets high-value niche drugs (biopharmaceuticals, complex generics, patented drugs going off-patent)
  • Outlay: Rs 15,000 crore over 6 years

Drug Regulation Framework

Drugs and Cosmetics Act, 1940

  • Principal legislation governing manufacture, distribution, sale, and import of drugs and cosmetics
  • Amended multiple times; sets standards for drug quality and safety
  • Schedule H, H1, X: prescription drug schedules
  • Schedule M: Good Manufacturing Practices (GMP) for drug manufacturing

Central Drugs Standard Control Organisation (CDSCO)

  • Under Ministry of Health and Family Welfare
  • India's national regulatory authority for drugs, cosmetics, diagnostics, devices
  • Headed by the Drugs Controller General of India (DCGI)
  • Approves new drugs for clinical trials and market authorisation (equivalent to US FDA)
  • Coordinates with State Drug Controllers for licensing manufacturing units

National Pharmaceutical Pricing Authority (NPPA)

  • Under Ministry of Chemicals and Fertilizers
  • Fixes prices of essential medicines under the National List of Essential Medicines (NLEM)
  • Regulates under Drug Prices Control Order (DPCO), 2013
  • Controls prices of ~900+ formulations (NLEM 2022 has 384 drugs)
  • Uses market-based pricing for NLEM drugs (ceiling = average of top three brands)

TRIPS Flexibilities and Compulsory Licensing

India's Patent Law and TRIPS

India's Patents Act, 1970 (amended 2005 to comply with TRIPS) has two key provisions that balance innovation and public health:

  • Section 3(d): Prevents "evergreening" — prohibits patents on new forms (salts, esters) of known substances unless they show significantly enhanced efficacy. Used to reject Novartis's application for Glivec (Gleevec) in the landmark Novartis AG v. Union of India (2013) Supreme Court judgment.
  • Section 84: Allows compulsory licensing if a drug is not available at a reasonably affordable price, or not adequately worked in India.

Natco Pharma vs Bayer: India's First Compulsory License (2012)

  • Date: Granted on 9 March 2012 (published 12 March 2012) by the Controller General of Patents
  • Drug: Sorafenib Tosylate (brand name: Nexavar) — used for kidney and liver cancer
  • Issue: Bayer's price was ~Rs 2.8 lakh per month; Natco offered it at Rs 8,880 per month (~3% of Bayer's price)
  • Royalty: Natco paid 6% of net sales to Bayer
  • Significance: India's first-ever compulsory license; demonstrated that TRIPS flexibilities (Doha Declaration) can be used for public health

Jan Aushadhi Scheme

Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP):

  • Launched in 2008; rebranded and expanded in 2016
  • Provides quality generic medicines at 50–90% cheaper than branded alternatives
  • Administered by Bureau of Pharma PSUs of India (BPPI) under Ministry of Chemicals and Fertilizers
  • Stores: 16,912 Jan Aushadhi Kendras (JAKs) across India (as of June 2025)
  • Target: 25,000 stores by March 2027
  • Product range: 2,110 medicines + 315 surgical consumables (as of 2025)
  • Savings to citizens: ~Rs 30,000 crore cumulative (2014–2024); Rs 7,350 crore in FY24 alone

Recent Developments (2024–2026)

India's Pharma Exports — $30.47 Billion (FY 2024–25)

India's pharmaceutical exports grew 9.4% to $30.47 billion in FY 2024–25. India is the world's third-largest pharmaceutical producer by volume (14th by value) and the largest supplier of generic medicines globally — contributing approximately 20% of global generic drug volumes and over 50% of global vaccine demand (measured in doses). Export destinations span 200+ countries, with the USA (34%), Europe (19%), and Africa significant markets.

The PLI (Production-Linked Incentive) Scheme for Pharmaceuticals (₹15,000 crore) specifically targets API (Active Pharmaceutical Ingredient) manufacturing — India imports approximately 65–70% of APIs from China, creating strategic vulnerability. PLI pharma has supported 72 approved projects for critical APIs, fermentation-based products, and biopharmaceuticals. India's API production for paracetamol, penicillin, and vitamins has increased, reducing Chinese dependence.

UPSC angle: India's pharma export value ($30.47 billion), global rank, API-China dependence, PLI pharma scheme, and biosimilars are Prelims and Mains facts.

Drugs (Amendment) Bill and Pharmaceutical Regulation 2024

The Ministry of Health and Family Welfare circulated the draft Drugs, Cosmetics and Medical Devices Bill in 2024, aimed at replacing the outdated Drugs and Cosmetics Act 1940. Key proposed changes include: a separate regulatory framework for medical devices (currently under drugs regulation); faster approval pathways for innovative drugs and biosimilars; strengthened pharmacovigilance (post-market surveillance); and enhanced penalties for spurious/adulterated drugs.

CDSCO (Central Drugs Standard Control Organisation) received enhanced capacity funding in 2024 to accelerate new drug approvals, which averaged 14 months in 2023 compared to 6–12 months in major regulatory markets (FDA: 6–10 months; EMA: 12–15 months). The National Pharmacovigilance Programme flagged over 12,000 adverse drug reaction reports in 2024.

UPSC angle: Drugs Act replacement bill, CDSCO approval timelines, pharmacovigilance, and medical devices separation are Mains GS-2/GS-3 content.

Jan Aushadhi Scheme — 14,000 Stores, ₹800 Crore Savings 2024

The Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) reached 14,000+ Jan Aushadhi Kendras (Janaushadhi stores) across 761 districts by 2024, making high-quality generic medicines available at 50–90% below market price. Monthly sales exceeded ₹125 crore in 2024. The scheme offers 2,000+ generic medicines and 300+ surgical consumables.

Cumulative savings to citizens since scheme launch have crossed ₹30,000 crore. The scheme's expansion to district hospitals, ESIC hospitals, and railway stations is increasing access. A 2024 DBT assessment found that Jan Aushadhi Kendras in tribal districts were the single most impactful healthcare access initiative for out-of-pocket expenditure reduction.

UPSC angle: PMBJP — 14,000 stores, ₹30,000 crore savings, 2,000+ medicines, and access for tribal/poor populations are Prelims data points; generic medicine policy and intellectual property are Mains content.

PYQ Relevance

  • 2019 GS3 Prelims: CDSCO, DCGI, NPPA — frequently asked institution identification questions.
  • Pharma industry, API dependence on China, and compulsory licensing (TRIPS flexibilities) are recurring GS3 Mains themes. Prepare: "India's pharmaceutical industry faces the challenge of raw material dependence. Discuss the policy measures to address API import dependence on China."
  • Jan Aushadhi scheme and generic medicine policy have been asked as short-answer questions under governance/welfare schemes in GS2/GS3.
  • The Natco vs Bayer compulsory license (2012) and Section 3(d) of the Patents Act are standard Prelims and GS3 content on TRIPS flexibilities and public health.

Exam Strategy

Key numbers:

  • China's share in India's API imports: ~70% overall, up to 87% for antibiotics
  • PLI for Bulk Drugs outlay: Rs 6,940 crore
  • Jan Aushadhi Kendras: ~16,912 (June 2025)
  • First compulsory license: March 9, 2012 (Natco vs Bayer, Nexavar)

Mains framing: India's pharma paradox = world's pharmacy for final products, but dependent on China for raw materials. PLI is the supply-side fix; Jan Aushadhi is the demand-side/access fix. Section 3(d) and compulsory licensing are the IP-flexibility tools protecting public health.

Link to Ujiyari.com for updates on PLI scheme progress, NLEM 2022 revisions, and the pharma sector in Union Budget 2025–26.